For the full year of 2025, we expect: Total revenue of approximately $335M, Technology revenue of approximately $220M and Adjusted EBITDA of approximately $41M…We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- HCAT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Health Catalyst price target lowered to $8 from $12 at Piper Sandler
- Health Catalyst price target lowered to $10 from $11 at Canaccord
- Health Catalyst price target lowered to $7 from $9 at RBC Capital
- Health Catalyst to Acquire Upfront Healthcare Services